
Precigen (PGEN) Stock Forecast & Price Target
Precigen (PGEN) Analyst Ratings
Bulls say
Precigen is positioned for strong long term growth, as evidenced by its recent financial results where it exceeded sales expectations and has a robust pipeline of clinical programs targeting multiple diseases. Its recently launched product, Papzimeos, has shown strong sales growth potential and the company has filed for an MAA with the EMA, which could vastly increase its addressable market. With favorable IP protection and potential expansion into pediatric patients, Precigen's stock presents as an attractive investment opportunity. However, potential risks include clinical, regulatory, commercial, partnership, financial, and intellectual property, as highlighted by management.
Bears say
Precigen is facing potential headwinds as they work to gain activation from targeted integrated delivery networks (IDNs) and community hospitals to reach key physicians for their AdenoVerse immunotherapy and UltraCAR-T therapies. Despite early promising launch metrics and positive enrollment for their Patient Support Hub, the activation of 93 targeted IDNs and community hospitals remains a rate limiting step for the company. Additionally, while management plans to provide updates on their PRGN-2009 clinical program in 2H26, Precigen's financials could be further strained if their first commercial product, Papzimeos, does not perform as expected.
This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.
Precigen (PGEN) Analyst Forecast & Price Prediction
Start investing in Precigen (PGEN)
Order type
Buy in
Order amount
Est. shares
0 shares